Document:

EX-10.1

 Exhibit 10.1 

SHARE REPURCHASE AGREEMENT 

This SHARE REPURCHASE AGREEMENT (this “Agreement”) is made as of November 5, 2018 by and between Installed
Building Products, Inc., a Delaware corporation (the “Company”) and PJAM IBP Holdings, Inc., an Ohio corporation (the “Selling Stockholder”). 

WITNESSETH: 

WHEREAS, (i) the Selling Stockholder wishes to sell an aggregate of 150,000 shares (the “Shares”) of common
stock, par value $0.01 per share, of the Company (the “Common Stock”) and (ii) the Company wishes to purchase the Shares from the Selling Stockholder, in each case upon the terms and subject to the conditions hereinafter set
forth. 
 WHEREAS, after due consideration, the Board of Directors and the Audit Committee of the Company have approved the
transaction contemplated hereby. 
 NOW, THEREFORE, in consideration of the premises and the representations, warranties, covenants
and undertakings contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Section 1.01. Definitions. For purposes of this Agreement, the terms defined in the preamble have the
respective meanings ascribed to them therein, and the following terms have the meanings set forth below: 
 “Action” means
any action, suit, proceeding, claim, arbitration, litigation or investigation, at law or in equity, in each case by or before any Person. 

“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with, such specified Person. 
 “Business Day” means
any day other than Saturday, Sunday or any day on which the Commission or New York Stock Exchange is closed due to public holiday. 

“Commission” means the Securities and Exchange Commission. 

“control” (and its derivatives) means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a Person, whether through ownership of voting equity interests, as trustee or executor, by contract or otherwise. 

“Governmental Authority” means any federal, state, local or foreign government or political subdivision thereof, or any
agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the
rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction. 

 “Law” means any statute, law, ordinance, regulation, rule, code,
order, constitution, treaty, common law, judgment, writ, decree, permit, license or other requirement or rule of law of any Governmental Authority. 

“Lien” means any mortgage, lien, pledge, claim, charge, security interest, adverse claim, transfer restriction or encumbrance
of any kind, other than restrictions under federal or state securities laws. 
 “Material Adverse Effect” means any change,
effect or circumstance that, individually or when taken together with all other such changes, effects or circumstances that occurred prior to the date of determination of the occurrence of the Material Adverse Effect, is or is reasonably likely to
materially delay or prevent the consummation of the transaction contemplated by this Agreement. 
 “Organizational
Documents” means the articles of incorporation, certificate of incorporation, certificate of formation, bylaws, memorandum or articles of incorporation, operating agreement, certificate of limited partnership, partnership agreement and all
other similar documents, instruments or certificates executed, adopted or filed in connection with the creation, formation or organization of a Person, including any amendments thereto. 

“Person” means any individual, corporation, partnership, limited liability company, trust, unincorporated association,
Governmental Authority or any agency, instrumentality or political subdivision of any governmental entity, or any other entity or body. 

“Purchase Price” means an amount per share equal to $34.11, which is equal to the last reported sales price of the
Company’s common stock as of November 2, 2018 ($35.16), less a discount of 3%. 
 “Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations thereunder. 
 ARTICLE 2 

PURCHASE AND SALE 

Section 2.01. Purchase and Sale. Upon the terms and subject to the conditions of this Agreement, and in reliance on
the representations, warranties and agreements set forth in this Agreement, at the Closing, (i) the Selling Stockholder shall sell, transfer and deliver the Shares to the Company, free and clear of all Liens and (ii) the Company shall
purchase and acquire the Shares from the Selling Stockholder, in each case in exchange for the payment by the Company, pursuant to Section 2.02(a), of an amount equal to the product of the Purchase Price and the number of
Shares being sold by the Selling Stockholder hereunder (such product, the “Aggregate Purchase Price”) to such Selling Stockholder on the Closing Date (defined below). 

Section 2.02. Closing. The closing of the transaction contemplated hereby (the “Closing”) shall
take place at the offices of the Company at 10:00 am ET on the third (3rd) Business Day following the date hereof or, if later, on such date and time as may be mutually agreed to by the Selling
Stockholder and the Company after satisfaction or waiver of all conditions set forth in Article 5 (the “Closing Date”). At the Closing: 

 (a) The Company shall deliver to the Selling Stockholder such Selling Stockholder’s
Aggregate Purchase Price by wire transfer of immediately available federal funds to an account designated by such Selling Stockholder. 
 (b)
The Selling Stockholder shall (i) deliver to the Company an executed receipt for the Aggregate Purchase Price; (ii) cause the Shares to be electronically transferred to the Company’s account at the transfer agent for the Company; and
(iii) furnish any other documents reasonably requested by the Company’s transfer agent in order to effect the transaction contemplated hereby. 

ARTICLE 3 

REPRESENTATIONS AND WARRANTIES OF THE SELLING STOCKHOLDER 

The Selling Stockholder represents and warrants to the Company as of the date of this Agreement and as of the Closing Date as follows: 

Section 3.01. Existence; Authorization. Such Selling Stockholder is an entity duly organized, validly existing and
in good standing under the Laws of its jurisdiction of organization, as applicable. Such Selling Stockholder has the requisite power and authority to enter into, execute and deliver this Agreement, to perform all of the obligations to be performed
by it hereunder, and to consummate the transaction contemplated hereby. This Agreement has been duly authorized, executed and delivered by it, and, assuming due authorization, execution and delivery by the Company, this Agreement constitutes a valid
and binding obligation of such Selling Stockholder, enforceable against it in accordance with its terms and conditions, except (i) as such enforcement is limited by bankruptcy, insolvency or other similar Laws affecting the enforcement of
creditors’ rights generally and (ii) for limitations imposed by general principles of equity. 

Section 3.02. No Conflicts. None of the execution, delivery or performance by such Selling Stockholder of this
Agreement, nor the consummation of the transaction contemplated hereby by such Selling Stockholder will conflict with, result in the breach of, constitute a default under or accelerate the performance required by the terms of: (i) any
Organizational Document of such Selling Stockholder; (ii) any judgment, order writ, decree, permit or license of any court or government, governmental or regulatory agency to which such Selling Stockholder or its assets may be subject;
(iii) any Law; (iv) any other contract, agreement, commitment or instrument to which such Selling Stockholder is a party or by which any of its assets are bound; or (v) constitute an event which, with or without due notice, the
passage of time or action by a third party, would result in any of the foregoing, except, with respect to clauses (ii) through (v), in any case where such conflict, breach, default or acceleration would not reasonably be expected to have a
Material Adverse Effect. Assuming the accuracy of the representations and warranties set forth in Article 4, the execution and delivery of this Agreement by such Selling Stockholder and the performance and consummation of the transaction
contemplated hereby do not require any registration, filing (except for filings pursuant to the Securities Exchange Act of 1934), qualification, consent, authorization or approval under any Law. Neither the execution and delivery of this Agreement
nor the performance or consummation of the transaction contemplated hereby by such Selling Stockholder will result in the creation of any Lien upon any of the Shares. 

 Section 3.03. Ownership of Shares. Such Selling Stockholder owns
all right title and interest (legal and beneficial) in and to the Shares being sold by such Selling Stockholder hereunder. Upon the Closing, the Company will acquire marketable title to such Shares free and clear of all Liens other than any Liens
created by the Company. 
 Section 3.04. Litigation. There is no Action pending or, to the knowledge of such
Selling Stockholder, threatened in writing against such Selling Stockholder or its Affiliates which, if adversely determined, would prevent the consummation of the transaction contemplated by this Agreement. There is no Action by such Selling
Stockholder pending or threatened against any other Person relating to the Shares owned by such Selling Stockholder. 

Section 3.05. Sophistication of Selling Stockholder. Such Selling Stockholder (either alone or together with its
advisors) has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the transaction contemplated by this Agreement. The Selling Stockholder has had the opportunity to ask questions
and receive answers concerning the terms and conditions of such transaction as it has requested. The Selling Stockholder has received all information that it believes is necessary or appropriate in connection with the transaction contemplated by
this Agreement. The Selling Stockholder acknowledges that it has not relied upon any express or implied representations or warranties of any nature made by or on behalf of the Company, whether or not any such representations, warranties or
statements were made in writing or orally, except as expressly set forth for the benefit of the Selling Stockholder in this Agreement. 

ARTICLE 4 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company hereby represents and warrants to the Selling Stockholder, as of the date of this Agreement and as of the Closing Date as follows:

 Section 4.01. Existence; Authorization. The Company is duly organized, validly existing and in good standing
under the Laws of the State of Delaware. The Company has the requisite power and authority to enter into, execute and deliver this Agreement, to perform all of the obligations to be performed by it hereunder, and to consummate the transaction
contemplated hereby. This Agreement has been duly authorized, executed and delivered by it, and, assuming due authorization, execution and delivery by the Selling Stockholder, this Agreement constitutes a valid and binding obligation of the Company,
enforceable against it in accordance with its terms and conditions, except (i) as such enforcement is limited by bankruptcy, insolvency or other similar Laws affecting the enforcement of creditors’ rights generally and (ii) for
limitations imposed by general principles of equity. 
 Section 4.02. No Conflicts. None of the execution,
delivery or performance by the Company of this Agreement, nor the consummation of the transaction contemplated hereby by the Company will conflict with, result in the breach of, constitute a default under or accelerate the performance required by
the terms of: (i) any Organizational Document of the Company; (ii) any judgment, order writ, decree, permit or license of any court or government, governmental or regulatory agency to which the Company or its assets may be subject;
(iii) any Law; (iv) any other contract, agreement, commitment or instrument to which the Company is a party or by 

 
which any of its assets are bound; or (v) constitute an event which, with or without due notice, the passage of time or action by a third party, would result in any of the foregoing, except,
with respect to clauses (ii) through (v), in any case where such conflict, breach, default or acceleration would not reasonably be expected to have a Material Adverse Effect. Assuming the accuracy of the representations and warranties set forth
in Article 3, the execution and delivery of this Agreement by the Company and the performance and consummation of the transaction contemplated hereby do not require any registration, filing (except for filings pursuant to the Securities
Exchange Act of 1934), qualification, consent or approval under any such Law. 
 Section 4.03. Litigation. There
is no Action pending, or to the knowledge of the Company, threatened against the Company or its Affiliates which, if adversely determined, would prevent the consummation of the transaction contemplated by this Agreement. 

ARTICLE 5 
 CONDITIONS TO
CLOSING 
 Section 5.01. Conditions to Obligation of the Company. The obligations of the Company to consummate
the transaction contemplated by this Agreement at the Closing are subject to each of the following conditions: 
 (a) Representations and
Warranties. The representations and warranties of the Selling Stockholder contained in this Agreement shall be true and accurate as of the Closing Date. 

(b) Legal Proceedings. No order of any nature issued by a court of competent jurisdiction restraining, prohibiting or affecting the
consummation of the transaction contemplated by this Agreement (a “Court Order”) shall be in effect, and no claim, suit, action, investigation, inquiry or other proceedings by any Governmental Authority or other person (a
“Governmental Proceeding”) shall be pending or threatened which questions the validity or legality of the transaction contemplated by this Agreement or prohibits the consummation of the Closing. 

Section 5.02. Conditions to Obligation of the Selling Stockholder. The obligations of the Selling Stockholder to
consummate the transaction contemplated by this Agreement at the Closing are subject to each of the following conditions: 
 (a)
Representations and Warranties. The representations and warranties of the Company contained in this Agreement shall be true and accurate as of the Closing Date. 

(b) Legal Proceedings. No Court Order shall be in effect, and no Governmental Proceeding shall be pending or threatened which questions
the validity or legality of the transaction contemplated by this Agreement or prohibits the consummation of the Closing. 
 ARTICLE 6

 GENERAL PROVISIONS 

Section 6.01. Termination. 

(a) This Agreement may be terminated and the transaction contemplated by it abandoned before the Closing (i) pursuant to the mutual
written consent of the Company and the Selling Stockholder at any time prior to the Closing, or (ii) upon prompt written notice by either the Company or the Selling Stockholder, if a Court Order shall be in effect or a Governmental Proceeding
shall be pending or threatened which questions the validity or legality of the transaction contemplated by this Agreement or prohibits the consummation of the Closing. 

 (b) This Agreement may be terminated, by prompt written notice, by (i) the Selling
Stockholder, if the Company is unable to take the action specified in Section 2.02(a) within five (5) Business Days following the date hereof, (ii) by the Company, if the Selling Stockholder is unable to take the
actions specified in Section 2.02(b) within ten (10) Business Days following the date hereof, or (iii) by either party, if such other party is unable to fulfill the conditions to Closing, as set forth in
Article 5, within ten (10) Business Days following the date hereof; provided, however, that no party may terminate this Agreement under this Section 6.01(b), if such party is otherwise unable to take the
actions required or meet the conditions to Closing of such party under this Agreement. 
 (c) If this Agreement is terminated as permitted by
Section 6.01(a) or Section 6.01 (b) above prior to the Closing, then the Company shall have no further obligation to buy, and the Selling Stockholder shall have no further obligation to sell, any
Shares. If this Agreement is terminated as permitted by Section 6.01(a) above prior to the Closing, no party to this Agreement shall have any liability or further obligation to any other party pursuant to this Agreement.

 Section 6.02. Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations
under this Agreement may be assigned or delegated, in whole or in part, by operation of Law or otherwise, by the Selling Stockholder or the Company without the prior written consent of the Company or the Selling Stockholder, as the case may be, and
any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement and all of its provisions shall be binding upon and inure to the benefit of the parties and their respective successors
and assigns. 
 Section 6.03. No Broker. Except as previously disclosed to the other party, no party has engaged
any third party as broker or finder or incurred or become obligated to pay any broker’s commission or finder’s fee in connection with the transaction contemplated hereby. 

Section 6.04. Amendment; Waiver. This Agreement may be amended or waived only if such amendment or waiver is in
writing and is signed, in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party or parties against whom the waiver is sought to be enforced. Any failure of the Company to comply with any obligation,
agreement or condition under this Agreement may only be waived in writing by the Selling Stockholder, and any such failure by the Selling Stockholder may only be waived in writing by the Company, but any such waiver shall not operate as a waiver of,
or estoppel with respect to, any subsequent or other failure. No failure by a party to take any action against any breach of this Agreement or default by the other party shall constitute a waiver of such party’s right to enforce any provision
of this Agreement or to take any such action. 
 Section 6.05. Notice. All notices, demands or other
communications to be given or delivered under or by reason of the provisions of this Agreement will be in writing and will be deemed to have been given when delivered personally, mailed by certified or registered mail, return receipt requested and
postage prepaid, or sent via a nationally recognized overnight courier, or sent via facsimile or electronic mail to the recipient. Such notices, demands and other communications will be sent to the address indicated below: 

 To the Selling Stockholder: 

PJAM IBP Holdings, Inc. 

495 South High Street, Suite 50 

Columbus, Ohio 43215 

Attention: Jeffrey W. Edwards 

With a copy to (which shall not constitute notice): 

Calfee, Halter & Griswold LLP 

1200 Huntington Center 
 41 South
High Street 
 Columbus, OH 43215-3465 

Attention: Steven C. Karzmer 

Facsimile No: 614-621-0010 

Email Address: skarzmer@calfee.com 

To the Company: 

Installed Building Products, Inc. 

495 South High Street, Suite 50 

Columbus, Ohio 43215 

Attention: Michael T. Miller 

With a copy to (which shall not constitute notice): 

Installed Building Products, Inc. 

495 South High Street, Suite 50 

Columbus, Ohio 43215 

Attention: General Counsel 

Section 6.06. Third Parties. Except as specifically set forth or referred to in this Agreement, nothing in this
Agreement, expressed or implied, is intended, or shall be construed, to confer upon or give to any person or entity other than the parties hereto and their successors or assigns, any rights or remedies under or by reason of this Agreement. 

Section 6.07. Governing Law; Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance
with the Laws of the State of New York, without regard to any conflicts of Laws principles which would result in the application of the Laws of any other jurisdiction. To the fullest extent permitted by Law, each party hereto waives any and
all rights such party may have to a jury trial with respect to any dispute arising under this Agreement or the transaction contemplated hereby. 

 Section 6.08. Entire Agreement. This Agreement sets forth the
entire agreement and understanding of the parties with respect to the subject matter of this Agreement and supersedes all prior agreements, promises, covenants, arrangements, communications, term sheets, memoranda of understanding, letters of
intent, representations or warranties, whether oral or written, by any party or any officer, employee or representative of any party. 

Section 6.09. Further Assurances. Each of the Company and the Selling Stockholder shall execute and deliver such
additional documents and instruments and shall take such further action as may be necessary or appropriate to effectuate fully the provisions of this Agreement. 

Section 6.10. Survival of Representations and Warranties. Expect as expressly set forth in
Section 6.01, all representations and warranties contained herein or made in writing by any party in connection herewith shall survive the execution and delivery of this Agreement and the consummation of the transaction
contemplated hereby. 
 Section 6.11. Severability. Whenever possible, each provision or portion of any provision
of this Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any
applicable Law, such invalidity, illegality or unenforceability shall not affect any other provision or portion of any provision in the applicable jurisdiction, and this Agreement shall be reformed to the minimum extent necessary so that this
Agreement may be construed and enforced in such jurisdiction to the maximum extent that such illegal or unenforceable provision may be enforced. 

Section 6.12. Headings; Interpretation. The headings of the Articles and Sections of this Agreement are inserted for
convenience only and shall not constitute a part of or affect in any way the meaning or interpretation of this Agreement. The words “include,” “includes” and “including” when used in this Agreement shall be deemed in
each case to be followed by the words “without limitation.” Defined terms used in this Agreement shall have the same meaning whether defined or used herein in the singular or the plural, as the case may be. Each party hereto acknowledges
that it has reviewed this Agreement prior to its execution and that changes were made to this Agreement based upon its comments. If any disputes arise with respect to the interpretation of any provision of this Agreement, the provision shall be
deemed to have been drafted by all of the parties and shall not be construed against any party on the basis that the party was responsible for drafting that provision. 

Section 6.13. Counterparts. This Agreement may be executed in two or more identical counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile and portable document format (.pdf) copies of this Agreement shall have the same force and effect as an original. 

[Signature Pages Follow]  

 IN WITNESS WHEREOF, the parties have executed this Share Repurchase Agreement as of
the date first above written. 
  

			
	COMPANY:
	
	INSTALLED BUILDING PRODUCTS, INC.
		
	By:	 	 /s/ Michael T. Miller

	Name:	 	Michael T. Miller
	Title:	 	Chief Financial Officer
	
	SELLING STOCKHOLDER:
	
	PJAM IBP HOLDINGS, INC.
		
	By:	 	 /s/ Jeffrey W. Edwards

	Name:	 	Jeffrey W. Edwards
	Title:	 	President

 Signature Page to Repurchase AgreementExecution
Version

 

SHARED
FACILITIES AND SERVICES AGREEMENT

 

This
Agreement is made as of August 17, 2017 (the Effective Date) by and between BioTime, Inc. (BioTime) and AgeX Therapeutics,
Inc. (AgeX).

 

Recitals

 

	A.	AgeX
    is a newly organized corporation that needs office and laboratory space and equipment, and the services of research, financial,
    management, and administrative personnel support;
	 	 
	B.	BioTime
    leases certain laboratory, office, and related work space at 1010 Atlantic Avenue, Alameda, California (the Premises)
    and has surplus capacity at the Premises; and
	 	 
	C.	BioTime
    has employees and contractors who provide research, financial, management, and administrative services and is willing to make
    a portion of their services available to AgeX;

 

1.
Office, Laboratory and Work Space.

 

(a)
BioTime agrees to permit AgeX to use the Premises concurrently with BioTime for the conduct of AgeX’s business operations,
but only to the extent that (a) the use is a business operation permitted to be conducted by BioTime under the lease of the Premises,
(b) AgeX uses the Premises in compliance with all applicable laws, ordinances, and regulations, (c) AgeX uses the Premises in
compliance with any and all rules and regulations of the landlord under BioTime’s lease of the Premises, (d) AgeX’s
use of the Premises does not interfere with BioTime’s use of the Premises.

 

(b)
BioTime and AgeX agree that the permission to use the Premises granted under this Agreement is in the nature of a license
only and is not a sublease or assignment of the lease under which BioTime occupies the Premises, and that AgeX shall not obtain
any rights, and is not assuming any obligations, under that lease.

 

(c)
The use of the Premises by AgeX shall be in a lawful, careful, safe, and proper manner, and AgeX shall not do or permit anything
to be done in or about the Premises that would increase the rate or affect any fire or other insurance covering the Premises.
AgeX shall not commit nor suffer any waste on the Premises.

 

(d)
BioTime does not represent or warrant that the Premises may be used for any particular use or purpose, and AgeX has made AgeX’s
own determination that the Premises may be lawfully used for AgeX’s purposes.

 

(e)
AgeX shall, at its sole cost and expense, comply with all laws, statutes, ordinances, and governmental rules, regulations,
or requirements now in force or that may hereafter be in force, and with the requirements of any board of fire insurance underwriters
or other similar bodies now or hereafter constituted, relating to, or affecting AgeX’s use of the Premises.

 

    	 

    	 

    

 

(f)
AgeX shall, at its sole cost and expense, promptly repair any damage to the Premises caused by any act or omission of AgeX
or its employees, agents, invitees, licenses, or contractors, including any acts or omissions of BioTime employees, contractors,
and agents arising in the course of performing services for or conducting the business of AgeX. Any and all repairs effected by
AgeX shall be performed in a professional workmanlike manner, by licensed contractors, in compliance with BioTime’s lease
of the Premises and all applicable statutes, codes, rules and regulations, and AgeX or AgeX’s contractors shall obtain all
permits and approvals of government agencies required by applicable laws in connection therewith.

 

(g)
BioTime deems any repairs required to be made by AgeX necessary, it may demand that AgeX make them, and if AgeX refuses or
neglects to commence such repairs and to complete them with reasonable dispatch, BioTime may make or cause such repairs to be
made. If BioTime makes or causes repairs to be made, BioTime shall not be responsible to AgeX for any loss or damage that may
accrue to AgeX’s business by reason of the repair work, and AgeX shall, on demand, immediately pay to BioTime the cost of
the repairs. AgeX waives the provisions of Sections 1941 and 1942 of the Civil Code of the State of California and all other statutes
or laws permitting repairs by a lessee at the expense of a lessor or to terminate a lease by reason of the condition of the Premises.
AgeX shall keep the Premises free from any liens arising out of any work performed, materials furnished, or obligations incurred
by AgeX.

 

(h)
AgeX shall not make or install any alterations, improvements, additions, or fixtures that affect the exterior or interior
of the Premises or any structural, mechanical, or electrical component of the Premises, or mark, paint, drill, or in any way deface
any floors, walls, ceilings, partitions, or any wood, stone, or iron work.

 

(i)
Under no circumstances shall AgeX bring onto the Premises any substances or materials that are characterized or defined as
“hazardous substances” or “hazardous materials” under any federal or state law or regulation pertaining
to the release of substances into the environment, except for cleaning materials, paints, and solvents that are used, stored,
and disposed of by AgeX in full compliance with applicable laws and BioTime’s lease of the Premises.

 

2.
Equipment and Supplies. BioTime agrees to permit AgeX to use BioTime’s office equipment, laboratory equipment, furniture,
laboratory supplies, and general office supplies to the extent that such use does not interfere with the use by the employees,
contractors, and agents of BioTime and other BioTime subsidiaries in the course of their business. BioTime shall have no obligation
to obtain or to provide AgeX with any additional equipment, furniture, or supplies. If AgeX requires and obtains equipment, furniture,
and supplies for its own use it may locate the same at the Premises subject to the conditions and limitations stated in Section
1 of this Agreement, and subject to the additional condition that BioTime shall have the right and sole discretion to (a) determine
where in the Premises AgeX may locate AgeX’s furniture, equipment, and supplies, and (b) preclude AgeX from bringing onto
or locating any furniture, supplies, or equipment in the Premises if BioTime determines that it would in any way interfere with
BioTime’s use of the Premises, violate any applicable laws, ordinances, and regulations, violate or conflict with any provisions
of BioTime’s lease of the Premises or any rules and regulations of the landlord under BioTime’s lease of the Premises,
conflict with any term or condition of any policy of casualty or liability insurance held by BioTime, or pose a hazard or other
risk to persons or property.

 

    	2

    	 

    

 

3.
Utilities. AgeX shall be responsible to determine that there is sufficient Utilities capacity in the Premises for purposes
of conducting AgeX’s use. Utilities includes electricity, gas, heat, air conditioning, hot and cold domestic water,
telephone, scavenger service, garbage removal, sewerage, and other similar services used on, in, or in connection with the Premises.
BioTime does not represent the availability or quantity of any Utilities in the Premises, and is not responsible for any interruption
of any Utility service.

 

4.
Services.

 

(a)
BioTime shall provide basic accounting, billing, bookkeeping, payroll, treasury, collection of accounts receivable (excluding
the institution of legal proceedings or taking of any other action to collect accounts receivable), payment of accounts payable,
and other similar administrative services, budget preparation, establishment of financial controls and reporting protocols and
procedures, financial reporting and securities registration under the Securities Exchange Act of 1934, as amended, and the Securities
Act of 1933, as amended (the Administrative Services) to AgeX. BioTime may also provide the services of attorneys, accountants,
and other professionals who may also provide professional services to BioTime and its other subsidiaries.

 

(b)
BioTime shall also provide AgeX with the services of its laboratory and research personnel (the Laboratory Services),
including BioTime employees and contractors, for the performance of research and development work for AgeX at the Premises. BioTime
employees and contractors who perform Laboratory Services for AgeX shall enter into agreements containing customary provisions
requiring the employees and contractors to (a) maintain the confidentiality and not to disclose AgeX trade secrets and other confidential
information, and (b) assign to AgeX all rights to any inventions and discoveries made by such employees and contractors in the
course of performing Laboratory Services for AgeX.

 

(c)
BioTime may, at the request of AgeX, provide AgeX the services of BioTime employees and contractors, including but not limited
to executive officers, for matters other than Administrative Services and Laboratory Services (Other Services), but BioTime
shall not be obligated to do so.

 

(d)
Administrative Services, Laboratory Services, and Other Services (collectively, Services) shall be provided by BioTime
employees or contractors engaged by BioTime to provide such Services for the operation of BioTime’s own business. BioTime
shall not be obligated to hire any additional employees or engage the services of any additional contractors to provide Services
to AgeX. Nothing in this Agreement shall preclude AgeX from hiring employees and engaging contractors directly for its own account
and at its own cost and expense.

 

    	3

    	 

    

 

(e)
AgeX shall be responsible for cooperating with BioTime’s officers, employees and contractors in such a manner as may
be reasonably required in order for the Services to be performed.

 

(f)
The Services shall be provided at the direction of AgeX; provided, that AgeX shall not request or direct any BioTime employee
or contractor to provide any Services or to take any other act that would violate any federal, state, or municipal law, statute,
ordinance, rule or regulation.

 

(g)
BioTime shall not be liable to AgeX for any loss or damages of any kind caused by, arising from, or in connection with (i)
the performance of Services performed by BioTime personnel, or the failure of any BioTime employee, contractor, or agent to perform
any Services, or (ii) any delay, error, or omission by any BioTime employee, contractor, or agent in the performance of Services
performed by BioTime personnel, except to the extent such loss or damage is the result of fraud, gross negligence or willful misconduct
by an BioTime employee, contractor, or agent.

 

5.
Use Fees.

 

(a)
AgeX shall pay BioTime the fees provided in this Section for the use of the Premises, equipment, supplies, professional services
(such as the services of attorneys, accountants, and consultants), and for the Services provided or agreed to be provided by BioTime
under this Agreement. For each billing period, BioTime shall equitably prorate and allocate its Employee Costs, Equipment Costs,
Insurance Costs, Lease Costs, Professional Costs, Software Costs, Supply Costs, and Utilities Costs, between BioTime and AgeX
based upon actual documented use and cost by or for AgeX or upon proportionate usage by BioTime and AgeX, as reasonably estimated
by BioTime. AgeX shall pay 105% of the allocated costs (the Use Fee). The allocated cost of BioTime employees and contractors
who provide Services shall be based upon records maintained of the number of hours of such personnel devoted to the performance
of Services.

 

(b)
The Use Fee shall be determined and invoiced to AgeX on a monthly basis for each calendar quarter of each calendar year (such
quarterly periods are sometimes referred to in this Agreement as “billing periods”). If this Agreement terminates
prior to the last day of a billing period, the Use Fee shall be determined for the number of days in the billing period elapsed
prior to the termination of this Agreement. Each invoice shall be payable in full by AgeX within 30 days after receipt. Any invoice
or portion thereof not paid in full when due shall bear interest at the rate of 15% per annum until paid, unless the failure to
make a payment is due to any inaction or delay in making a payment by BioTime employees from AgeX funds available for such purpose,
rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any
AgeX employee or agent.

 

(c)
In addition to the Use Fees, AgeX shall reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase
of office supplies, laboratory supplies, and other goods and materials and services for the account or use of AgeX, provided that
invoices documenting such costs are delivered to AgeX with each invoice for the Use Fee. Notwithstanding this paragraph, BioTime
shall have no obligation to purchase or acquire any office supplies or other goods and materials or any services for AgeX, and
if any such supplies, goods, materials or services are obtained for AgeX, BioTime may arrange for the suppliers thereof to invoice
AgeX directly.

 

    	4

    	 

    

 

(d)
Employee Costs means the salaries, wages, health insurance benefits, FICA, payroll taxes, workers compensation insurance premiums,
and similar costs payable by BioTime to or on account of its employees and contractors who perform Services for AgeX under this
Agreement during an applicable billing period, but excluding stock option, stock purchase, and similar equity participation plans.
Equipment Costs means all costs and expenses incurred by BioTime in acquiring, leasing, installing, maintaining, insuring,
repairing, and disposing of any laboratory, production, and office equipment, fixtures, and furnishings used by AgeX or used by
BioTime in the performance of Services. Insurance Costs means all insurance premiums of any kind incurred or paid by BioTime
for casualty insurance policies that insure BioTime and its subsidiaries, including AgeX, from the loss of or damage to the Premises,
equipment, fixtures goods, supplies, and other personal property of BioTime (except to the extent such premiums are included in
Lease Costs) that may be used by AgeX or by BioTime in the performance of Services, and liability coverage policies that insure
BioTime and its subsidiaries, including AgeX, from liability of any kind to third parties (except to the extent such premiums
are included in Lease Costs). Lease Costs means all of BioTime’s costs and expenses of leasing the Premises, including
all base rent, taxes, common area or other expenses, insurance and other costs payable by BioTime to the lessor of the Premises
under the lease of the Premises, but excluding (a) any repairs not required to be effected or paid for by AgeX under any other
provision of this Agreement, and (b) any alterations or improvements effected by BioTime for the exclusive use of BioTime and
its subsidiaries other than AgeX. Professional Costs means all costs and expenses incurred by BioTime for the services
of independent accountants, attorneys, and other consultants who provide professional or consulting services for the benefit of
AgeX. Software Costs means all costs and expenses, including but not limited to license fees, incurred by BioTime to acquire
and use any computer software or program of any kind that is used by AgeX or by BioTime in the performance of Services. Supply
Costs means all costs and expenses incurred by BioTime for the purchase and disposal of goods and materials of any kind, to
the extent used in the performance of Services or used by AgeX employees or contractors. Utilities Costs means all costs
and expenses incurred by BioTime for the use or availability of Utilities during an applicable billing period.

 

(e)
Billing Dispute Resolution. If a disagreement arises between BioTime and AgeX with respect to any Use Fees charged by BioTime
under this Section 5 or by AgeX under Section 6, and AgeX and BioTime management are not able to reconcile or resolve the matter
within sixty (60) days of the first written notice disputing any charge or portion of the Use Fee, AgeX and BioTime shall engage
the services of a firm of certified public accountants to review the charges at issue and determine the amount due, which determination
shall be final and binding on AgeX and BioTime. AgeX and BioTime shall cooperate with the accounting firm to resolve the matter,
including making all relevant books and records available to the accounting firm for inspection and copying, and making employees
with knowledge relevant to the matter in dispute reasonably available to discuss the matter with representatives of the accounting
firm. The fees and expenses of the accounting firm shall be shared equally by AgeX and BioTime; provided, however, that if the
accounting firm determines that Use Fees or other charges were overstated by more than five percent (5%) and the amount of the
overstatement exceeds $100,000, the party that submitted invoices for the excessive fees or charges shall pay 100% of the fees
and charges of the accounting firm related to that matter. AgeX and BioTime agree that they will engage BDO USA, LLP (“BDO”)
for such services, but if BDO declines to perform the services AgeX and BioTime shall cooperate to select an alternative accounting
firm.

 

    	5

    	 

    

 

6.
 Reciprocal Rights and Obligations.

 

(a)
AgeX agrees to permit BioTime and Other Subsidiaries to use AgeX’s office equipment, laboratory equipment, furniture,
laboratory supplies, and general office supplies to the extent that such use does not interfere with the use by the employees,
contractors, and agents of AgeX or AgeX subsidiaries in the course of their business. In the case of such use, (i) the provisions
of Section 2 of this Agreement shall apply as if all references in Section 2 to AgeX were references to BioTime or an Other Subsidiary,
and (ii) all references to BioTime in Section 2 were references to AgeX. “Other Subsidiary” means a subsidiary
of BioTime other than AgeX and other than a subsidiary of AgeX.

 

(b)
AgeX agrees to provide BioTime and Other Subsidiaries with Laboratory Services at the AgeX Premises subject to the same terms
and conditions as BioTime agrees to provide Laboratory Services to AgeX at the Premises. With respect to any Laboratory Services
provided by AgeX to BioTime or an Other Subsidiary, the provisions of Section 4 of this Agreement shall apply as if all references
to AgeX were references to BioTime and all references to BioTime were references to AgeX.

 

(c)
If AgeX provides BioTime or an Other Subsidiary with the use of AgeX’s office equipment, laboratory equipment, furniture,
laboratory supplies, and general office supplies, or Laboratory Services under this Agreement, the Use Fees provisions of Section
5 of this Agreement shall apply to such use and AgeX shall be paid Use Fees as if all references to AgeX were references to BioTime
or an Other Subsidiary and all references to BioTime were references to AgeX.

 

7.
Indemnification.

 

(a)
AgeX shall defend, indemnify, and hold harmless BioTime, BioTime’s shareholders, directors, officers, employees, and
agents (collectively, the Indemnified Parties) against and from any and all claims arising from AgeX’s use of the
Premises, or from any activity, work, or other thing done or permitted by AgeX on the Premises, including all activities, work,
and services performed by BioTime employees, contractors, and agents for AgeX except to the extent caused by BioTime’s willful
malfeasance or gross negligence. AgeX shall further defend, indemnify, and hold harmless the Indemnified Parties against and from
any and all claims arising from any breach or default in the performance of any obligation on AgeX’s part to be performed
under the terms of this Agreement, or arising from any act or omission (including, but not limited to negligent acts or omissions)
of AgeX, or of any officer, agent, employee, contractor, guest, or invitee of AgeX acting in such capacity. The indemnity provided
by this section shall include indemnification from and against all costs, attorneys’ fees, expenses, and liabilities incurred
in connection with or arising from any such claim or any action or proceeding brought thereon; and in any suit, action, or proceeding
brought against any of the Indemnified Parties by reason of any such claim, AgeX, upon notice from any of the Indemnified Parties,
shall defend the same at AgeX’s expense by counsel satisfactory to the Indemnified Parties. AgeX, as a material part of
the consideration to BioTime, hereby assumes all risk of damage to property or injury to persons in, upon, or about the Premises,
from any cause other than BioTime’s willful malfeasance or sole gross negligence.

 

    	6

    	 

    

 

(b)
BioTime shall not be liable for any injury to or damage to persons or property resulting from fire, explosion, falling plaster,
steam, gas, electricity, water, or rain that may leak from any part of the Premises or from the pipes, appliances, or plumbing
works therein or from the roof, street, or subsurface, or from any other place unless solely caused by or solely due to the gross
negligence of BioTime. BioTime and its agents and the other Indemnified Parties shall not be liable for interference with the
light or other incorporeal hereditament, loss of business by AgeX, or any latent defect in the Premises, any equipment, furnishings,
materials, or supplies. AgeX shall give prompt notice to BioTime in case of fire or accidents in the Premises or of defects therein
or in the fixtures, equipment, furniture, materials or supplies belonging to BioTime and used by AgeX.

 

(c)
AgeX shall be solely responsible for and shall indemnify, defend, and hold the Indemnified Parties and the owner of the Premises
and each partner, shareholder, member, trustee, employee and agent of the owner or the Premises (collectively, the Owner Indemnified
Parties) harmless from any against any claim, loss, damage, cost, expense, liability, or cause of action directly or indirectly
arising out of the use, generation, manufacture, storage, treatment, release, threatened release, discharge, disposal, transportation,
or presence of any oil, gasoline, petroleum products, flammable explosives, asbestos, urea formaldehyde insulation, radioactive
materials, hazardous wastes, toxic or contaminated substances, or similar materials, including, without limitation, any substances
which are hazardous substances, hazardous wastes, hazardous materials, or toxic substances under applicable environmental laws,
ordinances, or regulations (collectively, Hazardous Materials) caused directly or indirectly by AgeX, its employees, agents,
contractors, invitees, or assigns (other than any BioTime employees or agents performing BioTime rather than AgeX business) in,
on, or under any of the Premises, including, without limitation: (i) all consequential damages; (ii) the costs of any required
or necessary repair, cleanup, or detoxification of the Premises and the building and surrounding land in which the Premises are
located, and the preparation and implementation of any closure, remedial, or other required plans whether required under any Hazardous
Materials Laws or otherwise; and (iii) all court costs, including reasonable attorneys’ fees, paid or incurred by BioTime,
any other Indemnified Party, or any Owner Indemnified Party in connection with such claim.

 

(d)
BioTime shall defend, indemnify, and hold harmless AgeX, AgeX’s stockholders (other than BioTime), directors, officers,
employees, and agents (collectively, the AgeX Indemnified Parties) against and from any and all claims arising from any services
performed by AgeX employees, contractors, and agents for BioTime or an Other Subsidiary, except to the extent caused by AgeX’s
willful malfeasance or gross negligence. The indemnity provided by this section shall include indemnification from and against
all costs, attorneys’ fees, expenses, and liabilities incurred in connection with or arising from any such claim or any
action or proceeding brought thereon; and in any suit, action, or proceeding brought against any of the AgeX Indemnified Parties
by reason of any such claim, BioTime, upon notice from any of the AgeX Indemnified Parties, shall defend the same at BioTime’s
expense by counsel satisfactory to the AgeX Indemnified Parties.

 

    	7

    	 

    

 

8.
Term; Termination.

 

(a)
This Agreement shall commence on the Effective Date and may be terminated by either party by giving six months advance written
notice of termination to the other party.

 

(b)
Notwithstanding paragraph (a) of this Section 8, either party may terminate this Agreement immediately upon the occurrence
of a Default by the other party. A party shall be in Default if that party (i) fails to pay when due the Use Fee or any
other sum due under this Agreement, or fails to perform any other obligation under this Agreement, and such failure continues
for a period of five (5) days; provided, however, that if a party disputes the amount of the Use Fee or other charge within such
five day period, the running of such five day period shall commence upon the resolution of the dispute pursuant to Section 5(e);
(ii) becomes the subject of any order for relief in a proceeding under any Debtor Relief Law (as defined below); (iii) becomes
unable to pay, or admits in writing the party’s inability to pay, its debts as they mature; (iv) makes an assignment for
the benefit of creditors; (v) applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator,
rehabilitation, or similar officer for the party or for all or any part of the party’s property or assets, or any such officer
is appointed for such party or any part of its assets without the party’s consent and such appointment is not dismissed
or discharged within 60 calendar days; (vi) institutes or consents to any proceeding under any Debtor Relief Law with respect
to the party or all or any part of the party’s property or assets, (vii) becomes subject to any proceeding under any Debtor
Relief Law without the consent of the party if such case or proceeding continues undismissed or unstayed for 60 calendar days;
or (viii) dissolves or liquidates or takes any action to dissolve or liquidate. As used in this Agreement, the term Debtor
Relief Law shall mean the Bankruptcy Code of the United States of America, as amended, or any other similar debtor relief
law affecting the rights of creditors generally.

 

(c)
AgeX may terminate this Agreement on six months written notice to BioTime given after such date on which BioTime ceases to
consolidate the financial statements of AgeX with the financial statements of BioTime under generally accepted accounting principles
in the United States.

 

(d)
The obligations of AgeX under Sections 5 and 6 and to pay for any repairs of the Premises required to be paid by AgeX under
this Agreement shall survive termination of this Agreement.

 

9.
No Third Party Beneficiaries. The parties to this Agreement are BioTime and AgeX, and no other person or entity, whether a
partner, member, stockholder, officer, director, employee, contractor, agent, or business invitee of AgeX or otherwise, shall
have any rights or be entitled to any benefits under this Agreement, except for the rights of Indemnified Parties and Owner Indemnified
Parties under Section 7.

 

    	8

    	 

    

 

10.
Characterization of Relationship. It is the intent of the parties that the business relationship created by this Agreement,
and any related documents is solely that of a commercial agreement between BioTime and AgeX and has been entered into by both
parties in reliance upon the economic and legal bargains contained in this Agreement. None of the covenants contained in this
Agreement is intended to create a partnership between BioTime and AgeX, to make them joint venturers, to make either party an
agent, legal representative, partner, subsidiary, or employee of the other party or to make either party in any way responsible
for the debts, obligations, or losses of the other party.

 

11.
Binding on Successors and Assigns. This Agreement shall be binding on each party and the party’s successors and assigns.

 

12.
Integration. This Agreement constitutes all of the understandings and agreements existing between the parties concerning the
subject of this Agreement and the rights and obligations created under it. Neither party has made or relied upon any agreement,
warranty, representation, promise, or statement, whether oral or written, not expressly included in this Agreement.

 

13.
Waivers, Delays, and Omissions. One or more waivers, consents, or approvals by any party of any covenant, condition, act,
or breach under this Agreement shall not be construed as a waiver, consent, or approval of any subsequent condition, covenant,
act, or breach or as a consent or approval to the same or any other covenant or condition. This Agreement and any term of this
Agreement may be amended, discharged, or terminated only by a written instrument signed by the parties against whom enforcement
of such amendment, discharge, or termination is sought. No delay or omission to exercise any right, power, or remedy accruing
to any party upon any breach or default of the other party under this Agreement shall impair any such right, power, or remedy
of the party not in breach or default.

 

14.
References. References in this Agreement to sections, paragraphs, subparagraphs, and exhibits are references to sections,
paragraphs, and subparagraphs in this Agreement and exhibits attached to this Agreement unless specified otherwise.

 

15.
Section Headings. Section headings are for the convenience of the parties and do not form a part of this Agreement.

 

16.
Construction. The parties agree that this Agreement is a negotiated agreement, with each party free to review and negotiate
each section of the Agreement and otherwise clarify all sections of the Agreement that appear to the party (at the time of signing)
to be ambiguous or unclear. Both parties shall be deemed to be the drafting parties, and the rules of construction to the effect
that any ambiguities are to be resolved against the drafting party or parties shall not be employed in the interpretation of this
Agreement.

 

    	9

    	 

    

 

17.
Unenforceable Provisions. If all or part of any one or more of the provisions contained in this Agreement is for any reason
held to be invalid, illegal, or unenforceable in any respect, the invalidity, illegality, or unenforceability shall not affect
any other provisions, and this Agreement shall be equitably construed as if it did not contain the invalid, illegal, or unenforceable
provision.

 

18.
Attorneys’ Fees. It is expressly agreed that if this Agreement is referred to an attorney to collect any amount due
under this Agreement, or to enforce or protect any rights conferred upon BioTime by this Agreement AgeX promises and agrees to
pay on demand all costs, including without limitation, reasonable attorneys’ fees, incurred by BioTime in the enforcement
of BioTime’s rights and remedies under this Agreement. In the event an action is brought to enforce or interpret the provisions
of this Agreement, the prevailing party in such action shall be entitled to an award of its attorneys’ fees and costs incurred
in such action, including any fees and costs incurred in any appeal and in any collection effort.

 

[Signatures
Found on the following page]

 

    	10

    	 

    

 

IN
WITNESS WHEREOF the parties have executed this Agreement as of the Effective Date.

 

	BioTime,
    Inc. 	 
	 	 	 
	By:	/s/
    Aditya P. Mohanty	 
	 	Aditya
    P. Mohanty	 
	 	Co-Chief
    Executive Officer	 
	 	 	 
	AgeX
    Therapeutics, Inc.	 
	 	 	 
	By:	/s/
    Michael D. West	 
	 	Michael
    D. West,	 
	 	Chief
    Executive Officer	 

 

[Signature
Page to the Shared Facilities Agreement]

 

    	11

    	 

    

 

FIRST
AMENDMENT TO THE SHARED FACILITIES AND SERVICES AGREEMENT

 

This
First Amendment to the Shared Facilities and Services Agreement (“First Amendment”) is made and entered into as of
August 30, 2018 (the “Effective Date”) by and between BioTime, Inc. (BioTime) and AgeX Therapeutics,
Inc. (AgeX).

 

Recitals

 

WHEREAS,
the parties previously entered into a Shared Facilities and Services Agreement (“Agreement”) on August 17, 2017 (“Original
Effective Date”).

 

WHEREAS,
AgeX needs office and laboratory space and equipment, and the services of research, financial, management, and administrative
personnel support;

 

WHEREAS,
BioTime leases certain laboratory, office, and related work space at 1010 Atlantic Avenue, Alameda, California (the Premises)
and has surplus capacity at the Premises; and

 

WHEREAS,
BioTime has employees and contractors who provide research, financial, management, and administrative services and is willing
to make a portion of their services available to AgeX.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained herein, the Parties agree as follows:

 

		1.	Section
                                         8(a) of the Agreement shall be deleted and replaced in its entirety by:

 

“This
Agreement commenced on the Original Effective Date and may be terminated by either party by providing six months advance written
notice of termination to the other party after August 31, 2020.

 

		2.	Section
                                         8(c) of the Agreement shall be deleted and replaced in its entirety by:

 

“AgeX
may terminate this Agreement on six months written notice to BioTime after such date on which BioTime ceases to consolidate the
financial statements of AgeX with the financial statements of BioTime under generally accepted accounting principles in the United
States; provided, that after such termination, to the extent that BioTime is required by generally accepted accounting
principles in the United States to report any financial information of AgeX, AgeX agrees to provide such information prepared
in accordance with generally accepted accounting principles within thirty (30) days of each quarter end. BioTime may disclose
such information as required by any law, regulation or security exchange rule in any country.”

 

		3.	Capitalized
                                         terms used herein have the same meaning given to them in the Agreement.

 

		4.	Other
                                         than expressly amended herein, the Agreement remains in full force and effect.

 

		5.	This
                                         First Amendment may be executed in any number of counterparts.

 

[SIGNATURES
FOUND ON THE FOLLOWING PAGE]

 

    	12

    	 

    

 

IN
WITNESS WHEREOF the parties have executed this Agreement as of the Effective Date.

 

	BioTime,
    Inc.	 
	 	 	 
	By:	/s/
    Aditya P. Mohanty	 
	 	Aditya
    P. Mohanty	 
		Co-Chief
    Executive Officer 	 
	 	 	 
	AgeX
    Therapeutics, Inc.	 
	 	 	 
	By:	/s/
    Michael D. West	 
	 	Michael
    D. West,	 
	 	Chief
    Executive Officer	 

 

[SIGNATURE
PAGE TO THE FIRST AMENDMENT TO THE SHARED FACILITIES AGREEMENT]

 

    	13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]